Psychotropic Medication and GDR Support for Nursing Homes (F605, formerly F758)
What changed
On April 28, 2025, CMS began surveying unnecessary psychotropic medication use under F605 (Chemical Restraints / Unnecessary Psychotropic Medications). The former F758 guidance was folded into F605, and F757 now covers non-psychotropic unnecessary drugs only. CMS also expanded the "convenience" concept to include medication use that causes sedation or reduces the effort staff need to meet a resident's needs, and emphasized the resident's right to be informed and to accept or decline a psychotropic medication before it is started or increased.
Source: CMS QSO-25-14-NH (revised March 10, 2025), cms.gov
What surveyors look for (summary of 42 CFR 483.45(e))
A diagnosed, documented condition for every psychotropic medication
Gradual dose reductions and behavioral interventions, unless clinically contraindicated
PRN psychotropic orders limited to 14 days unless the prescriber documents a rationale and duration
PRN antipsychotic orders limited to 14 days and not renewed without a prescriber evaluation
This page is educational and is not legal or regulatory advice.
How US Psychiatry PLLC helps
Psychotropic review: a board-certified psychiatrist or PMHNP reviews residents on psychotropic medications for indication, dose, duration, and monitoring.
GDR plans: documented reduction attempts with dates, outcomes, and next steps, or a clear clinical contraindication.
PRN clean-up: evaluation and documentation for PRN psychotropic and antipsychotic orders approaching 14 days.
Informed-participation documentation: notes that reflect resident or representative discussions.
IDT and QAPI support: participation in behavior meetings and psychotropic committees.
Staff education: non-pharmacological approaches for dementia-related distress.
Ways to work with us
Psychotropic & GDR review — one-time review of residents on psychotropics with a written summary for your team
Ongoing coverage — GDR tracking built into regular psychiatric rounds
Pre-survey consult — focused review ahead of your survey window
No published rates. Request a proposal below.
F605 Psychotropic & GDR Readiness Checklist
For each resident on a psychotropic medication:
Diagnosis and specific target symptoms documented
Non-pharmacological interventions tried and documented
Resident/representative informed and given the chance to accept or decline before start or increase
GDR attempted within required timeframes, with date, outcome, and plan; or clinical contraindication documented by the prescriber
PRN psychotropic orders ≤14 days, or rationale and duration documented
PRN antipsychotic orders ≤14 days; renewals only after prescriber evaluation
Monitoring for side effects (sedation, falls, metabolic, movement) documented
Pharmacist MRR recommendations addressed
Behavior monitoring data reviewed in IDT / psychotropic committee
Educational only. Source: CMS State Operations Manual Appendix PP, F605 (Rev. 229, eff. April 28, 2025).